HOME >> BIOLOGY >> NEWS
Caught sleeping: Study captures virus dormant in human cells

Princeton scientists have taken an important step toward understanding a virus that infects and lies dormant in most people, but emerges as a serious illness in transplant patients, some newborns and other people with weakened immune systems.

The virus, called human cytomegalovirus, enters the bone marrow and can hide there for a lifetime. Until now, however, scientists had not been able to study the virus in its latent stage because it infects only humans and does not readily infect or become dormant in laboratory strains of bone marrow cells.

In a study published online Nov. 27, Felicia Goodrum, a postdoctoral fellow, and Tom Shenk, a professor of molecular biology, demonstrated a laboratory system for studying the virus in its latent stage. They showed they could establish a latent infection in freshly collected bone marrow cells and then retrigger an active infection. They drew on their system to discover a set of genes that the virus uses in its latent state and that may give the virus its great capacity for stealth.

Knowing what genes the virus uses to hide and re-emerge could give pharmaceutical companies targets for designing drugs that disrupt those mechanisms. "So you could dream that some day in the future we could clear the virus from a person and not just treat the symptoms that occur when the virus re-emerges," said Shenk.

Cytomegalovirus is in a broad family of herpes-related viruses, which includes the virus that causes chicken pox and shingles. The only treatment doctors currently have for cytomegalovirus is an antiviral drug called gancyclovir, which stops the virus from replicating during its active infection phase, but has no effect during the latent stage, when the virus does not replicate.

Another possible use for the research would be to develop a diagnostic test that indicates when the virus is likely to reactivate itself. If scientists could pinpoint genes that turn on just in advance of reactivation,
'"/>

Contact: Steven Schultz
sschultz@princeton.edu
609-258-5729
Princeton University
2-Dec-2002


Page: 1 2 3

Related biology news :

1. Penn Scientists Show How Mistakes In Protein Folding Are Caught By "Protein Cages" Called Chaperonins
2. Study: Emission of smog ingredients from trees is increasing rapidly
3. Study explores gene transfer to modify underlying course of Alzheimers disease
4. Study reveals why eyes in some paintings seem to follow viewers
5. Study by Israeli scientists provides insight on DNA code
6. Study reveals first genetic step necessary for prostate cancer growth
7. Study of flu patients reveals virus outsmarting key drug
8. Study in Science reveals recreational fishing takes big bite of ocean catch
9. Study suggests cell-cycle triggers might be cancer drug targets
10. Study narrows search for genes placing men at increased risk for prostate cancer
11. Study links high carbohydrate diet to increased breast cancer risk

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Caught sleeping Study captures virus dormant human cells

(Date:6/18/2013)... environmental engineer has been awarded a $394,300 grant ... water quality and flow in the new facilities ... Kruzic, UT Arlington associate professor of civil engineering, ... add monochloramine to the water in an effort ... stations and pipelines. Adding monochloramine is widely practiced ...
(Date:6/18/2013)... The National Institutes of Health has awarded $12.7 ... a selection of pharmaceutical industry compounds to explore ... including Alzheimer,s disease, Duchenne muscular dystrophy and schizophrenia. ... Uses for Existing Molecules, is led by the ... funded by the NIH Common Fund. , The ...
(Date:6/18/2013)... and 10% of breast and ovarian cancers are familial ... are attributable to inherited mutations from the parents in ... these mutations, PARP inhibitors, which are currently in clinical ... new option for personalised cancer treatment, an alternative to ... fraction of these patients generate resistance to the drug ...
Breaking Biology News(10 mins):UT Arlington research to benefit quality, flow in 150-mile Integrated Pipeline 2NIH to fund collaborations with industry to identify new uses for existing compounds 2NIH to fund collaborations with industry to identify new uses for existing compounds 3NIH to fund collaborations with industry to identify new uses for existing compounds 4An article in 'Cell' reveals a new resistance mechanism to chemotherapy in breast and ovarian cancer 2
(Date:6/20/2013)... Dental decay is the number one ... For Dr. Crisafulli of Crisafulli Dental those statistics are no ... the world and implemented a cavity prevention program developed by ... by up to 74% . The system is ... finally found a solution to dental decay that works,” says ...
(Date:6/19/2013)... IL (PRWEB) June 19, 2013 For ... offers Waterless Bead Baths using metallic beads ... less electricity, and do not require germicides. Yet, the ... and, because the bath is always ready unlike a ... beads create a dry bath, which eliminates the contamination ...
(Date:6/19/2013)... 2013 Research and ... addition of the "Global Biometric Systems ... to their offering.      (Logo: ... protection and old security practises such as ... the growth of biometric technologies in last ...
(Date:6/19/2013)... 19, 2013  Continuing its long history of proven ... Beckman Coulter , Inc. announces the U.S. Food and ... AccuTnI+3 troponin I assay for use on its Access ... on Beckman Coulter,s troponin I test for ... the proven performance to continue providing dependability to laboratories ...
Breaking Biology Technology:Crisafulli Dental Launches Ground Breaking Cavity Prevention Program That Can Lower Decay Rates by 74% 2Cole-Parmer Introduces Eco-Friendly Waterless Bead Baths 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 2Global Biometric Systems Market Forecast Report - Opportunities to 2018 3Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3
Cached News: